EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Synaptosomal‐Associated Protein 25 kDA (SNAP‐25) Levels in Cerebrospinal Fluid: Implications for Alzheimer's Disease Diagnosis and Monitoring

Sofia Hjorth Wolner, Helena Sophia Gleerup, Christian Sandøe Musaeus, Peter Høgh, Nicholas J Ashton, Ann Brinkmalm, Johanna Nilsson, Lana Grötschel, Henrik Zetterberg, Kaj Blennow, Steen Gregers Hasselbalch, Anne Byriel Walls und 1 weitere

Synapse · 2025-03 · 79 (2)

DOI: 10.1002/syn.70010 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Synapse, online erschienen am 06.02.2025. Verfasst von Sofia Hjorth Wolner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Synaptosomal-Associated Protein 25, Alzheimer Disease, Dementia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Alzheimer Foundation, Alzheimer's Drug Discovery Foundation, Familjen Erling-Perssons Stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synaptic degeneration has been linked to cognitive decline. The presynaptic protein, synaptosomal‐associated protein 25 kDA (SNAP‐25), is crucial for synaptic transmission and has been suggested as a biomarker in Alzheimer's disease (AD). In the current study, we investigated the ability of SNAP‐25 to differentiate between heterogenous dementia etiologies and whether SNAP‐25 could be a staging marker in AD. SNAP‐25 in the cerebrospinal fluid (CSF) from a retrospective ( n = 187) and a prospective ( n = 134) cohort was investigated with immunoprecipitation mass spectrometry (IP‐MS) and single‐molecule array (Simoa), respectively. Both cohorts consisted of healthy controls (HC) and patients with cognitive decline of different etiologies. CSF SNAP‐25 concentration was higher in AD and non‐neurodegenerative diseases (i.e., vascular dementia) compared with controls but did not differ between AD and non‐AD neurodegenerative diseases. We found a trend toward an association between SNAP‐25 and disease burden when comparing HC, mild cognitive impairment due to AD, and AD. CSF SNAP‐25 concentrations were strongly associated with CSF phosphorylated tau (p‐tau) concentrations, thus strengthening the link between synaptic dysfunction and tau pathophysiology in AD. Our initial findings suggest that SNAP‐25 may be a potential biomarker for differentiating AD from dementia due to other etiologies. However, due to the significant association between SNAP‐25 and p‐tau proteins, the clinical utility of SNAP‐25 as a diagnostic biomarker for AD may be limited, while SNAP‐25 may be useful for monitoring disease progression or treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Synaptosomal-Associated Protein 25Alzheimer DiseaseDementiaBiomarkersDiagnosis, DifferentialRetrospective StudiesProspective Studiestau ProteinsDisease ProgressionCross-Sectional StudiesHumansMaleFemaleMiddle AgedAged

Stichwörter der Autor:innen

Alzheimer's diseaseCSFSNAP‐25diagnosis

Substanzen

SNAP25 protein, humanSynaptosomal-Associated Protein 25Biomarkerstau Proteins

Autor:innen und Institutionen

  • Danish Dementia Research Centre, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Regional Dementia Research Centre, Department of Neurology, Zealand University Hospital, Roskilde, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Institute of Psychiatry, Psychology and Neuroscience Maurice Wohl Institute Clinical Neuroscience Institute, King's College London, London, UK.
  • NIHR Biomedical Research Centre for Mental Health and Biomedical Research Unit for Dementia at South London and Maudsley NHS Foundation, London, UK.

ORCID-Profile: Anja Hviid Simonsen

Förderung

  • Swedish Alzheimer Foundation
  • Alzheimer's Drug Discovery Foundation
  • Familjen Erling-Perssons Stiftelse
  • UK Dementia Research Institute
  • NIA NIH HHS
  • European Union Joint Programme - Neurodegenerative Disease Research
  • Bluefield Project
  • Absalon Foundation

Zitieren

APA

Wolner, S. H., Gleerup, H. S., Musaeus, C. S., Høgh, P., Ashton, N. J., Brinkmalm, A., Nilsson, J., Grötschel, L., Zetterberg, H., Blennow, K., Hasselbalch, S. G., Walls, A. B., & Simonsen, A. H. (2025). Synaptosomal‐Associated Protein 25 kDA (SNAP‐25) Levels in Cerebrospinal Fluid: Implications for Alzheimer's Disease Diagnosis and Monitoring. Synapse, 79(2). https://doi.org/10.1002/syn.70010

Vancouver

Wolner SH, Gleerup HS, Musaeus CS, Høgh P, Ashton NJ, Brinkmalm A, et al. Synaptosomal‐Associated Protein 25 kDA (SNAP‐25) Levels in Cerebrospinal Fluid: Implications for Alzheimer's Disease Diagnosis and Monitoring. Synapse. 2025;79(2). doi:10.1002/syn.70010

BibTeX
@article{Wolner2025,
  author = {Wolner, Sofia Hjorth and Gleerup, Helena Sophia and Musaeus, Christian Sandøe and Høgh, Peter and Ashton, Nicholas J and Brinkmalm, Ann and Nilsson, Johanna and Grötschel, Lana and Zetterberg, Henrik and Blennow, Kaj and Hasselbalch, Steen Gregers and Walls, Anne Byriel and Simonsen, Anja Hviid},
  title = {Synaptosomal‐Associated Protein 25 kDA (SNAP‐25) Levels in Cerebrospinal Fluid: Implications for Alzheimer's Disease Diagnosis and Monitoring},
  journal = {Synapse},
  year = {2025},
  volume = {79},
  number = {2},
  doi = {10.1002/syn.70010}
}
Kostenlos starten →